Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension.
about
Assessment of hepatic fibrosis with magnetic resonance elastography.Mesenteric and splenic contributions to portal venous CT perfusion in hepatic diffuse disease.Nonmuscle myosin II regulates migration but not contraction in rat hepatic stellate cellsSensitivity to endothelin-1 is decreased in isolated livers of endothelial constitutive nitric oxide synthase knockout mice.Therapeutic potential of targeting the renin angiotensin system in portal hypertension.Major adverse events, pretransplant assessment and outcome prediction.Glutamine prevents oxidative stress in a model of portal hypertensionEfficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologistsIntrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability.NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.Chronic intermittent hypoxia aggravates intrahepatic endothelial dysfunction in cirrhotic rats.The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis.Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.Role of gap junctions modulating hepatic vascular tone in cirrhosis.The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.Diabetes enhances the intrahepatic vascular response to endothelin-1 in cirrhotic rats: association with the ETA receptor and pERK up-regulation.Insulin resistance in patients with cirrhosis and portal hypertension
P2860
Q30493170-82AE3D49-EAC6-4F85-B0DA-5988C50D4D47Q34733162-2642A93E-3DF6-4ADE-B8BA-BF4D0EEFA51DQ35173002-94A277FE-95DB-41D4-ACEC-20A1059644DDQ35220034-25A2D807-7346-4350-9442-91393F870E58Q36769062-1922FCEA-2A99-45E2-BC76-04BECCC8856FQ37688276-27CBF849-F16E-4C09-84A3-C2F400F1299AQ40976036-06D46105-C849-4F3A-9007-58DE88CC2A86Q41334703-E85D981B-19FF-4D00-9BF5-E5D3F805C4A4Q41416491-306CC58A-07DA-422F-8375-19A9F886D1E3Q41848559-6DBD966D-60F1-46B5-B611-6F78E970817FQ42379057-1B8960D5-3303-4B06-B4D5-8F23149E96C4Q42667685-68D9286D-2D2F-4B7D-83B7-B9FBF9B25A0FQ43173631-FF186707-80D9-403D-AC5F-9BB66A1605C2Q43240136-7FF8920D-CEB2-4E07-85DF-C8DBED4D1659Q45092997-17D511C8-E7D2-493E-A904-E4DA5F64876AQ50245155-7BFBB037-7B4D-4F2D-82C7-F9FE5C6AC391Q50277167-C020576B-9DEE-4A5C-AD87-B7FFA6404BDAQ54231145-5D7477D1-4682-49CA-A463-D2317F2D2FAAQ54342105-D86882FB-0F8F-439A-9D98-8436264A4520Q54367967-01522D69-98EA-4D61-A3E9-905FD48C92A4Q59288256-C6889CEB-4B70-47AB-B9D6-6399CEB70393
P2860
Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Increased hepatic resistance: ...... herapy of portal hypertension.
@ast
Increased hepatic resistance: ...... herapy of portal hypertension.
@en
type
label
Increased hepatic resistance: ...... herapy of portal hypertension.
@ast
Increased hepatic resistance: ...... herapy of portal hypertension.
@en
prefLabel
Increased hepatic resistance: ...... herapy of portal hypertension.
@ast
Increased hepatic resistance: ...... herapy of portal hypertension.
@en
P1476
Increased hepatic resistance: ...... therapy of portal hypertension
@en
P2093
Jaime Bosch
Manuel Hernández-Guerra
P304
P356
10.1097/01.MCG.0000155513.17715.F7
P433
P577
2005-04-01T00:00:00Z